Evaluation of the Invest in Play Program - a New Parent Intervention for Children With Problem Behavior

NCT ID: NCT06984809

Last Updated: 2025-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-25

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to test if the invest in Play (iiP) parent program can reduce problem behaviors in children and improve parenting practices in families with children who show challenging behaviors. The main questions it aims to answer is:

• Does the iiP program reduce children's problem behaviors?

Researchers will compare families in the iiP program to families in a control group to see if the program leads to better outcomes for children and parents.

Participants will be randomly assigned to either the iiP program group or the control group and complete surveys before and after the program to see if iiP is reducing children's problem behaviors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Problem Behavior Attention Deficit and Disruptive Behavior Disorders

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

parent intervention parent practices emotion regulation parent-child relationship parental attributions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

The control condition will receive usual care, e.g., further assessments, school meetings, individual care and/or psycho education.

Group Type NO_INTERVENTION

No interventions assigned to this group

Invest in Play group

Intervention group receiving Invest in Play (iiP), a 12 session program provided weekly to parents with children with problem behavior.

Group Type EXPERIMENTAL

Intervention

Intervention Type BEHAVIORAL

The intervention group will receive Invest in Play (iiP), a 12 session group-based parent program, which is led by two trained group leaders.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intervention

The intervention group will receive Invest in Play (iiP), a 12 session group-based parent program, which is led by two trained group leaders.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Invest in Play (iiP)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Parents of children between 6-12 years of age referred to out-patient clinics for treatment of behavioural problems.
* Children scoring above a pre-defined mean cut off score (over the 90 percentile) on the Eyberg Child Behavior Inventory (ECBI; Eyberg \& Ross, 1978) based on Norwegian norms (Reedtz et al., 2008), as reported by parents.

Exclusion Criteria

\- Severe developmental delay (in children or parents), autism spectrum disorder, inability to understand Norwegian, or other reasons why the parent(s) are not expected to benefit from group therapy.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NORCE Norwegian Research Centre AS

OTHER

Sponsor Role collaborator

NTNU Health (sponsor)

UNKNOWN

Sponsor Role collaborator

University of Tromso

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lene-Mari P. Rasmussen, Ph.d

Role: PRINCIPAL_INVESTIGATOR

UiT The Arctic University of Norway

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Haukeland university hospital, department of mental health care for children and adolescents

Bergen, , Norway

Site Status RECRUITING

Helse Fonna HF, BUP Stord

Haugesund, , Norway

Site Status NOT_YET_RECRUITING

Helse Nord-Trøndelag HF, Barne- og ungdomspsykiatrisk avdeling (BUP)

Namsos, , Norway

Site Status ENROLLING_BY_INVITATION

OUS/PHA/BUPA/BUP Oslo Nord

Oslo, , Norway

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Norway

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kurt Henrik Dalmo, Ph.d.

Role: CONTACT

Phone: +4777660306

Email: [email protected]

Geraldine Mabille, Ph.d.

Role: CONTACT

Phone: +4777645864

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Bjørn Brunborg

Role: primary

Ingvild Kaldråstøyl

Role: primary

Helge Børresen

Role: backup

Gaute Skribekk, lic.jur

Role: primary

Marianne Robertsen

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-957314

Identifier Type: OTHER

Identifier Source: secondary_id

2024/785387

Identifier Type: -

Identifier Source: org_study_id